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Abstract
Purpose: To evaluate feasibility and toxicity of carbon ion therapy for treatment of sinonasal malignancies. First
site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local
control hence calls for dose escalation which has so far been hampered by accompanying acute and late toxicity.
Raster-scanned carbon ion therapy offers the advantage of sharp dose gradients promising increased dose
application without increase of side-effects.
Methods: Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010.
Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST.
Results: Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiation. All patients
had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose
was 73 GyE mostly in mixed beam technique as IMRT plus carbon ion boost. Median follow- up was 5.1 months
[range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher
grade acute reactions; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from
alterations of taste, all symptoms had resolved at 8 weeks post RT. Overall radiological response rate was 50% (CR
and PR).
Conclusion: Carbon ion therapy is feasible; despite high doses, acute reactions were not increased and generally
resolved within 8 weeks post radiotherapy. Treatment response is encouraging though follow-up is too short to
estimate control rates or evaluate potential late effects. Controlled trials are warranted.
Background
Sinonasal malignancies include malignant tumours of
various histologies in the nasal cavity and paranasal
sinuses. Squamous cell carcinomas account for the
majority of these tumours [1-3], however, also various
rare histologies such as adenoidcystic carcinoma, aesthe-
sioneuroblastoma, and mucosal melanoma are found.
Due to limited accessibility of these sites and late
occurrence of symptoms, patients are mostly diagnosed
with advanced disease [4-6]. Traditionally, surgery has
been the primary treatment modality for this disease.
Faced with predominantly advanced tumour stages sur-
gical resection is limited by the proximity of various cri-
tical structures such as eye and optic pathways.
Extensive surgery in advanced sinonasal tumours can be
very mutilating; in view of patients’ quality of life, radi-
cality of surgical resection can therefore rarely be
achieved. In addition, mortality and complication rates
are not insignificant [7] and substantially increasing with
patient age [8].
Local relapse rates following surgical treatment of 50 -
60% [4,9] are consequently high; in high-risk situations
such as involved or close surgical margins and advanced
tumour stage, adjuvant radiotherapy is recommended
[9-11].
In conventional treatment techniques, sufficient dose
application in radiation therapy has been limited by
dose to surrounding organs at risk and subsequent early
and late toxicity leading to loss of vision in approxi-
mately one third of patients [12,13]. With the advent of
more sophisticated radiation treatment techniques like
3D-conformal RT [14,15], intensity-modulated RT
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years, toxicities were effectively reduced while local con-
trol remained more or less stable [10,20]. First and pre-
dominant site of treatment failure in paranasal sinus
and nasal cavity cancer remains in-field [21,22]. Multi-
variate analyses found local control strongly dependent
on applied dose stressing the need for further dose esca-
lation in RT [22]. Particle therapy was shown to
improve local control in relatively radioresistant cancers
of the head and neck [23,24], while increased biological
efficiency (RBE) and physical properties of dose distribu-
tions with extremely sharp gradients also argue strongly
in favour of this treatment [25-28]. With the permanent
availability of particle therapy by the establishment of
hospital-based sites, this treatment becomes more fre-
quently though not commonly available. We would like
to report initial outcome of carbon ion therapy of sino-
nasal malignancies with respect to acute toxicity and
initial response at our facility.
Methods
Patients
29 patients with histologically proven or incompletely
resected malignant tumors of the paranasal sinuses and
nasal cavity were treated mostly with a combination of
IMRT and carbon ion therapy or carbon ion therapy
alone from November 2009 to August 2010. Prior RT
was not an exclusion criterion if another course of
radiation therapy was justifiable. Toxicity was assessed
at completion of combination treatment and on each
follow-up visit. Treatment response was evaluated
according to RECIST based on contrast-enhanced MRI-
scans at the first follow-up visit. Treatment-related
toxicity was prospectively collected and patient data was
retrospectively analysed.
Radiotherapy
Immobilization/planning examinations
Patients were immobilized using individual scotch cast
or thermoplastic head masks with shoulder fixation.
Planning examinations consisted of a planning CT scan
(3 mm slice thickness) with the patient positioned in the
individual fixation device and contrast-enhanced MRI
for 3D image correlation as a standard.
Target volumes/dose prescription
CTV1 (carbon ion boost) includes the macroscopic
tumor/prior tumor bed with special focus on the R2/R1-
area. In malignant salivary gland tumors, neural pathways
to the base of skull (cave: perineural invasion and skip
lesions) are also included in the CTV1. PTV1 consists of
a 3 mm margin around the CTV1 but does not extend
into critical organs at risk (i.e. brain stem, spinal cord).
We prescribe a dose of 24 GyE carbon ions in 3 GyE/
fraction (5 fractions per week) to the CTV1, we aim at
covering the CTV1 with the 95% prescription isodose.
The carbon ion boost is given at the HIT (Heidelberg
ion beam therapy centre).
CTV2 includes CTV1 with safety margins along typi-
cal pathways of spread. Only ipsilateral nodal levels (II
and III) are included, however, in case the primary
tumor is/was located at midline or crossing midline,
bilateral nodal levels II and III are covered. In case there
is pathological lymph node involvement, additional
nodal levels are covered as indicated. CTV2 also encom-
passes the complete surgical operational area and takes
account for set-up variations, hence corresponds to the
PTV2 (CTV2 = PTV2).
50 Gy IMRT (inversely planned step-and-shoot or
tomotherapy technique) in 25 fractions (5 fractions per
week) are prescribed to the CTV2 (coverage at least
with the 90% prescription isodose) taking into account
doses applied by daily image guidance with MV-cone-
beam CT. If necessary, daily pretreatment online correc-
tion of translational vectors was carried out.
In case of patients undergoing a second course of
radiation, CTV1 includes the visible tumor only. Doses
are prescribed individually depending on prior RT and
interval between the two treatments. No elective nodal
irradiation was performed in patients receiving carbon
ions only.
Particle therapy
The carbon ion therapy is given at the HIT after inverse
treatment planning in active beam application (raster-
scanning method) [29] with a horizontal, fixed beamline
at 5 fractions per week (Tue - Sat).
A monoenergetic carbon ion beam with a full-width/
half-maximum (FWHM) of 5 mm is extracted from the
accelerator system (synchrotron) and magnetically
deflected to subsequently scan all planned iso-energetic
slices roughly corresponding to the tumor’s radiological
depth. Using this method, almo s ta n yd e s i r e dd o s ed i s -
tribution can be created and dose to surrounding critical
structures can be minimized.
Inverse treatment planning was carried out on a dedi-
cated Siemens treatment planning system (TPS
®). As
ion beams exhibit an increased biological effective dose
depending on various factors, these need to be included
within the planning algorithm. Therefore, TPS
® addi-
tionally offers methods for inverse treatment planning
and biological RT treatment optimization for particle
therapy. In addition, steering parameters for scanned
ion beams need also be calculated by the TPS.
Daily image guidance consisted of orthogonal x-ray
controls in treatment position with the x-ray tube/
receptor mounted on a robot to allow imaging in almost
any treatment table position. After acquisition of ortho-
gonal x-rays, an automatic 2D-3D pre-match was carried
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radiotherapist/radiation oncologist with regard to bony
anatomy. Manual adjustment of the match was carried
out on-line and the resulting correction vector, includ-
ing rotations, subsequently applied to the patient posi-
tion. Patient position was controlled in each session and
shifts were always corrected using a robotic table allow-
ing position correction in six degrees of freedom.
Intensity-modulated radiotherapy (IMRT)
IMRT is carried out at a 6 MV linear accelerator after
inverse treatment planning either in step-and-shoot
technique or as tomotherapy at 5 fractions per week
(Mon - Fri). Image guidance consists of regular
MV-cone-beam CTs with online correction prior to
treatment application in 3 degrees of freedom. Doses
delivered by the MV-imaging were taken into account
for the total applied dose.
Radiotherapy plan evaluation/dose constraints
IMRT and carbon ion treatment plans had to be opti-
mized and evaluated separately according to the follow-
ing criteria: <20% of the CTV1 should receive ≥110% of
the prescribed dose, <5% of CTV1 or CTV2 should
receive ≤90% of the prescribed dose, and <2% or 2 cc of
tissue outside the CTVs should receive ≥110% of the
prescribed dose to the CTV1. In addition, the following
normal tissue constraints served as a basis for individual
plan evaluation. These constraints were applicable for
the summation (carbon ion and photon IMRT) plan at
standard fractionation (2 Gy/fraction).
￿ Spinal cord: the dose to any point within the spinal
cord should not exceed 5045 Gy to any volume larger
than 0.03 cc.
￿ Brain stem: the tolerated dose is 54 Gy; maximum
tolerated dose in volumes of ≤1cc: 60 Gy.
￿ Optic chiasm/optic nerves: maximum dose to these
structures should be ≤54 Gy, in case this dose limit can-
not be kept without compromising target volume cover-
age, these issues were discussed with the patient and
decisions made accordingly.
￿ Eyes: maximum doses ≤45 Gy to the posterior bulb/
retina; doses to the whole eye were reduced as low as
reasonably achievable without compromising target
volume coverage
￿ Parotid glands: mean dose to at least one gland
below 26 Gy; alternatively at least 20 cc of the combined
volume of both parotid glands to <20 Gy or at least 50%
of one gland to <30 Gy.
Follow-up
First follow-up examination including clinical examina-
tion and diagnostic, contrast-enhanced MRI was carried
out 6 weeks post completion of radiation treatment.
Further controls including MRI were scheduled for 3, 6,
and 12 months thereafter.
Patients were also encouraged to undergo regular
check-ups incl. full ENT and ophthalmologic clinical
examinations in regular intervals.
Analysis
Evaluation of toxicity was carried out according to NCI
CTCAE v. 4.0, treatment was evaluated using the
RECIST-criteria [30] based on available follow-up scans
(CT or MRI) and clinical examinations 6-8 weeks post
completion of therapy.
Results
Twenty-nine patients with sinonasal malignancies were
treated from 11/2009 to 08/2010. Median age was 57
years [range: 20 - 77 years]. Median follow-up was 5.1
months [range: 2.4 - 10.8 months]. All patients were
alive at last follow-up time. Fifty-nine percent (17 pts)
received treatment as definitive radiation therapy either
due to surgical inoperability or R2-resections, 9 patients
were treated for locally recurrent disease; 2 patients
received carbon ion therapy as a second course of radia-
tion. Most tumours were located in the maxillary sinus,
however due to extensive disease, the primary site could
not be identified in 3 patients. Most of the patients had
histologically proven adenoid cystic carcinoma or malig-
nant melanoma, tumour stages were advanced (T4) in
most of the cases. Four patients had undergone surgical
orbital exenteration, 2 patients induction chemotherapy
with no sign of persistent tumour in one patient.
Another patient received radiation therapy as combined
radioimmunotherapy with cetuximab weekly (table 1).
Most patients (25/29 pts) received mixed-beam radio-
therapy consisting of IMRT either in step-and-shoot
technique (22 pts) or tomotherapy (3 pts) and carbon ion
boost. Four patients received carbon ion therapy only.
Median total dose applied was 73 GyE [range: 70 - 75
GyE]. Treatment volumes were large with a median
CTV1 volume of 129.5 cc and CTV2 volume of 395.8 cc
(table 2). Carbon ion therapy was applied over 2 non-
coplanar fields after inverse treatment planning using sin-
gle-beam optimization (26 pts) and intensity-modulated
particle therapy (IMPT) in 2 cases. Only one patient with
pansinus tumour needed 3 fields. Treatment times
including patient positioning and position verification
were typically between 35 and 55 minutes per fraction
compared to approx. 20 min for standard IMRT. Table 3
summarizes dose-volume statistics for respective critical
structures. Figure 1, 2, and 3 show an exemplary carbon
ion and IMRT (Figure 4, 5, and 6) treatment plan of a
patient with adenoidcystic carcinoma.
At first follow-up 6 weeks post completion of radia-
tion therapy, two patients showed complete, 6 patients
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disease, among them the patients with chordoma, chon-
drosarcoma, and osteosarcoma. Eleven of the postopera-
tively treated patients and the patient who had
undergone induction chemotherapy for undifferentiated
paranasal sinus carcinoma showed no signs of disease.
One patient with malignant melanoma however devel-
oped a local recurrence within the high dose area (total
dose 73.1 GyE) as well as distant metastases (liver,
bone) at first follow-up, another patient also with malig-
nant melanoma developed distant metastases four
months after completion of radiotherapy.
Treatment was tolerated well with 7 cases of acute
grade 3 toxicity (mucositis: 5 pts; dysphagia: 2 pts) at
completion of radiotherapy. There were no treatment
interruptions or any case of grade 4 or 5 acute toxicity.
Most patients developed moderate mucositis, dermatitis,
xerostomia, or dysgeusia leading to mild or moderate
dysphagia. Two patients, both of them with extensive
treatment fields, needed supportive therapy by parent-
eral nutrition or feeding tube. Due to the close proxi-
mity of the treatment fields, 6 patients developed
radiation-induced conjunctivitis (table 4). Six to eight
weeks (first follow-up) post treatment, only 3 patients
showed grade 3 reactions (serous otitis) with a drainage
tube in place. Many patients still complained of residual
alterations in taste, however all of them described these
symptoms as gradually resolving; 12 patients still had
mild xerostomia and 2 patients presented with residual
mucositis at their first follow-up. There were no cases
of early visual impairment or residual conjunctivitis
(table 5).
Discussion
Treatment for sinonasal malignancies remains a com-
plex issue even in the days of modern surgical and
radiotherapeutic techniques. Hence Chen and co-work-
ers [20] were asking a very important question: Are we
making progress?
Rates of in-field local recurrences call for further dose
escalation within the treatment volume [21,22]. How-
ever, especially in tumours of the paranasal sinuses and
nasal cavity, treatment-related toxicity has so far limited
attempts of dose escalation. With the introduction of
modern radiotherapy techniques, side-effects could be
reduced while local control remained largely unchanged
[20]. The clinical establishment of carbon ion therapy
however, has seen the improvement of local control
rates in adenoidcystic carcinoma [23,24,31,32] where in
contrast to neutron therapy [33-36], no increased rates
of toxicity were observed. Also, physical properties of
heavy charged particles such as carbon ions as well as
Table 1 patient baseline characteristics
site maxillary sinus 19 pts
nasal cavity 3 pts
ethmoid sinus 3 pts
sphenoid sinus 1 pt
pansinus 3 pts
histology adenoidcystic carcinoma 20 pts
malignant melanoma 3 pts
undifferentiated carcinoma 1 pt
chordoma 1 pt
chondrosarcoma 1 pt
osteosarcoma 1 pt
ameloblastic carcinoma 1 pt
malignant peripheral nerve sheath
tumour
1p t
stage T4 18 pts
T3 4 pts
T2 1 pt
N+ 1 pt
not applicable 5 pts
therapy primary 20 pts
local relapse 9 pts
reirradiation 2 pts
R1-resected 11 pts
R2-resected/definitive RT 17 pts
orbital exenteration 4 pts
post-induction 2 pts
comb. Radioimmunotherapy 1 pt
Table 2 treatment characteristics; C12: = carbon ion
therapy
median dose/GyE
or Gy
range/GyE or Gy
C12 24 21 - 60
IMRT 49 47 - 51
total 73 70 - 75
median volume/cc range/cc
CTV1 129.5 41.9 - 422.0
CTV2 395.8 100.2 - 1246.8
combined
treatment
25 pts (8 fractions
C12)
step& shoot IMRT 22 pts
tomotherapy 3 pts
C12 only 4 pts (15-20
fractions)
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Page 4 of 10Table 3 treatment plan parameters; C12:= carbon ion therapy
max (Gy/GyE)
ipsilateral eye contralateral eye ipsilateral optic nerve contralateral optic
nerve
optic chiasm brain stem spinal cord ipsilateral
lens
C12 median 21,5 11,5 17,3 13,6 8,3 14,1 0 7,4
max 50,1 48,5 53,9 51,1 51,9 49,4 14,7 23,3
min 2,3 2 0 0 0 0 0 0
IMRT median 45,7 27,9 42,4 32,5 28,6 38,9 33,9 23,8
max 53,3 45,5 50 51,8 45,5 46,3 40,7 41,1
min 31,4 10,2 4,6 4,2 4,1 22,1 0 17,5
summation median 63,6 35,7 56,2 43,1 31,5 47,5 30 22,3
max 74 65,3 67 61,5 58,1 65,9 49,7 59,9
min 18,6 0 4,6 0 0 0 0 4,6
max (Gy/GyE) median (Gy/GyE)
contralateral
lens
ipsilateral mandibular
joint
contralateral mandibular
joint
ipsilateral parotid contralateral
parotid
ipsilateral
eye
contralateral
eye
C12 median 8,2 20,7 1,1 2,1 0 5,3 2
max 40 25,9 23,5 23,2 24,9 22,6 31,2
min 0 6,5 0 0 0 0 0
IMRT median 12,7 49,6 8,3 23 8,7 25,4 15,5
max 30,1 51 53,1 32,5 27,2 36,1 27,1
min 10,7 24,7 4,7 1,7 1,3 3 2,2
summation median 15 31,2 7,5 21,3 8 21,1 16,9
max 40,8 75,5 76,6 47,6 48,5 46,3 38,7
min 2 7,5 0,2 0 0 0 0
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0active scanning methods allow generation of highly con-
formal dose distributions and extremely steep dose gra-
dients. Therefore, application of heavy ion therapy for
the treatment of paranasal sinus tumours seemed
obvious.
While it could be shown in planning comparisons that
particle dose distributions are indeed superior to
conventional and IMRT treatment plans [27,28,37], this
still needs to be clinically demonstrated. With the more
widespread availability of particle therapy in the near
future - by 2012, there will be 5 centres offering particle
therapy in Germany alone - treatment-related toxicity
will be an important issue in the treatment of this dis-
ease. Since it will take years to evaluate treatment late
Figure 2 61 year-old patient with malignant melanoma pT4
cN2b: carbon ion 3-field IMPT (sagittal).
Figure 1 61 year-old patient with malignant melanoma pT4
cN2b: carbon ion 3-field IMPT (axial).
Figure 4 61 year-old patient with malignant melanoma pT4
cN2b: step-and-shoot IMRT plan using 9 coplanar beams, dose
legend in Gy (axial).
Figure 3 61 year-old patient with malignant melanoma pT4
cN2b: carbon ion 3-field IMPT (coronal).
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ment-related acute reactions with past experience in the
photon world at an early point in time as a predictor of
late toxicity.
In the 29 patients treated in this series, no unexpected
toxicity was seen: as reported by other groups
[15,16,19,38,39], the vast majority of patients showed
mucositis of some degree, a few groups did not observe
any or only marginal grade 3 mucositis [15,19], however
it needs to be emphasized that these reports included
no [15] or less than 50% [19] T4 tumours, hence irradia-
tion volumes will be smaller and consequently rates of
higher grade acute mucositis will be lower. The rate of
grade 3 toxicity in our patient cohort was 17.2% (5/29
pts) and ≥grade 2 65.5% (19/29 pts), which is in good
agreement with results reported by Zenda et al (mucosi-
tis CTC grade 3: 21%) with a similar dose and target
volume concept [40]. Though the rate of acute toxicity
grade 2/3 in our patients is somewhat higher than
reported by Wu et al [39], the authors did not describe
their dose concept and it is unclear which total dose
these patients received. Of course, occurrence of
acute reactions is dependent on treated volume and
absolute dose applied. Median doses reported by the
various groups have been up to approximately 70 Gy
[17-20,22,38]. Although postoperative radiation therapy
could improve local control in sinonasal malignancies,
first site of treatment failure still remains in-field, there-
fore further dose escalation above 65 GyE [18] is justi-
fied. In view of the median dose of 73 GyE and a
median treatment volume (CTV2) of approximately 400
cc in our patient cohort the rate of mucositis observed
is hardly surprising and within the published range.
Although maximum doses to the ipsilateral eye were
comparatively high [10,17,18], still we have only
observed one case of xerophthalmia (CTC grade 1) and
no ocular/visual toxicity so far. High maximum total
doses to optic structures were caused by extensive
tumours directly adjacent to the optic apparatus; how-
ever, due to steep gradients achieved by carbon ion and
IMRT treatment, these doses were only received by
small parts of the organ and median (total) doses were
generally kept low (21.1 GyE ipsilateral and 16.9 GyE
contralateral eye). Xerostomia and alterations of taste
had also largely resolved 6-8 weeks post completion of
radiotherapy. So far, there is no indication of lingering
higher grade toxicity.
U n f o r t u n a t e l y ,t h e r ei sv e r yl i t t l ed a t aa v a i l a b l ef o r
treatment of tumours in the paranasal sinuses or nasal
cavity using either protons or heavier charged particles.
Neutron therapy did yield comparatively good control
rates, due to increased acute and late toxicity [34,41] as
well as handling propertiest h i st r e a t m e n tw a sa b a n -
doned in many places. Four groups have reported their
results with particle therapy in this setting [32,38].
Mizoe et al evaluated two hypofractionated dose escala-
tion regimens for advanced head and neck cancers of
various histologies, among them squamous cell carcino-
mas, adenoidcystic carcinomas, and mucosal malignant
melanomas. Nine of the thirty-six reported cases were
located in the paranasal sinuses or nasal cavity. In their
analysis, there were 7 cases of grade 3 skin and 1 case
Figure 5 61 year-old patient with malignant melanoma pT4
cN2b: step-and-shoot IMRT plan using 9 coplanar beams, dose
legend in Gy (sagittal).
Figure 6 61 year-old patient with malignant melanoma pT4
cN2b: step-and-shoot IMRT plan using 9 coplanar beams, dose
legend in Gy (coronal).
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was not analysed with regard to tumour site [32]. Also,
this working group employed carbon ions only whereas
we have mostly used a mixed beam regimen in order to
account for potential locoregional tumour spread. One
would of course already expect some degree of mucosi-
tis caused by the photon part of our treatment, therefore
comparison of our results with carbon ion therapy only
is difficult. In addition, HIMAC uses passive beam appli-
cation: although efficiency of the beam is low requiring
higher beam intensities than spot scanning methods,
robustness of the system is high in view of potential
positioning errors or anatomical changes (tissue swelling
etc). Therefore systematic image guidance (i.e. pre-treat-
ment position controls) needs to be implemented to
maintain target coverage/normal tissue sparing and
h e n c el o wt o x i c i t yp r o f i l ei na c t i v eb e a ma p p l i c a t i o n
systems.
Zenda et al. recently published a pilot study using pro-
ton therapy to 60 GyE in 15 fractions as a nonsurgical
treatment alternative reporting similar treatment-related
acute toxicity as in our cohort with promising control
rates [40]. Truong and co-workers treated patients with a
combination of photon and proton therapy and observed
a grade 3 mucositis rate of 30% and ≥grade 2 of 70% [38].
Apart from one patient who developed meningitis due to
cerebrospinal fluid leak, these authors could not find any
major late toxicity associated with their treatment at
longer follow-up. Seven out of 36 patients developed
acute radiation-related toxicity (conjunctivitis and
Table 4 toxicity at completion of RT
CTC grade
toxicity I (pts) II (pts) III (pts)
mucositis 9 14 5
dermatitis 17 8 0
desquamation 1 0 0
dysphagia 8 5 2
xerostomia 22 0 0
otitis 0 3 0
conjunctivitis 0 6 0
serous otitis 0 2 0 (prae-therapeutic: 2 pts)
watering eyes 2 0 0
xerophthalmia 1 0 0
lymphoedema 3 0 0
transitory change/loss of taste 12 10 0
prophylactic feeding tube 3 pts
weight loss 10 pts 2-8 kg
praetherapeutic mandibular joint fibrosis 5 pts
Table 5 toxicity at 8 weeks post completion of RT
CTC grade
toxicity I (pts) II (pts) III (pts)
mucositis 2 0 0
dermatitis 0 0 0
desquamation 0 0 0
dysphagia 5 0 0
xerostomia 12 0 0
otitis 2 3 0
hearing impairment 2 0 0
conjunctivitis 0 0 0
serous otitis 1 0 0 (prae-therapeutic: 2 pts)
watering eyes 0 0 0
xerophthalmia 1 0 0
lymphoedema 0 0 0
transitory change/loss of taste 16 0 0
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treated with a combination of photon and proton RT.
However, 13 out of the 36 patients developed late ocular
complications; absolute doses to the GTV and optic
structures were also seen as an important predictor of
late radiation induced complications [42]. Though visual
impairment most often develops after a longer interval
post treatment - approximately 20 months in the cohort
described by Hasegawa et al, it may be observed as early
as 5 months post RT [43] with the latency period corre-
lating to the dose to the optic structures [42].
In the available literature, there is also little data with
regard to treatment response. In patients with visible
residual tumour, we have observed an overall response
rate of 7/17 patients (41.2%) including patients with
chordoma and osteosarcoma, where fast tumour shrink-
age is generally not expected. Complete responses were
seen in a patient with large adenoidcystic carcinoma and
ameloblastic carcinoma of the maxillary sinuses. One
patient with R1-resected malignant melanoma however
did develop an in-field recurrence in addition to distant
disease progression; another patient with malignant mel-
anoma also showed distant failure but stayed locally
controlled. Overall treatment response after carbon ion
therapy only was reported at 80,6% in the Japanese ser-
ies [32], again, this is given for the whole patient cohort,
analysis of the subset of tumours in the paranasal
sinuses/nasal cavity is not available. As mentioned
before, in this group consisted of more patients with
squamous cell carcinoma and malignant melanoma [32].
Local tumour control at the time of evaluation was
achieved in all but one patient (96,6%). However, due to
short follow-up in our series, estimates of local control
and comparison with results achieved by other groups
(up to 86% at 2 years [14,15,17,18] and up to 74% at 5
years [18-21]) are not possible. All in all our tumour
control so far seems encouraging though further follow-
up is definitely needed to support initial results.
Our patient cohort mainly consisted of patients with
adenoidcystic carcinoma of the paranasal sinuses and only
to a small part of malignant mucosal melanoma and other
rare histologies. This cohort does probably not reflect
overall incidence of tumour entities in these sites, where
squamous cell carcinoma and to a lesser extent malignant
melanoma would be expected to be more frequent [1,9].
However, our main objective was to investigate accompa-
nying early toxicity of our treatment for irradiation in this
area of the body, therefore actual histologies are not as
relevant. Another limitation to this analysis is, of course,
comparatively short follow-up of our patients and no con-
clusion regarding potential late effects can be drawn yet.
In view of the fact this treatment is comparatively new
and will be more commonly available in the future, we still
think potential side effects need early attention to prevent
a large number of patients being treated before evaluation
might reveal higher toxicity rates.
So radiotherapy for sinonasal cancers has dramatically
improved within the past decade: treatment-related side-
effects could be reduced by the introduction of new and
sophisticated treatment techniques. Faced with some-
times unsatisfactory local control in this disease though,
there is room still for improvement, which will also be
based on dose escalation.
The best way to evaluate the risk benefit ratio of this
treatment though is treatment of this indication within
clinical trials. Hence, a phase II trial evaluating acute
and late toxicity of combined IMRT and carbon ion
boost for this indication is currently under way and will
open for patient accrual by the end of 2010.
Conclusion
Despite high delivered dose, this therapy is feasible,
acute reactions were not increased as compared to 3D
and IMRT treatment techniques and generally resolved
within 6-8 weeks post radiotherapy. Treatment response
is encouraging though follow-up is too short to estimate
control rates or evaluate potential late effects. Con-
trolled trials are needed to investigate these issues in a
controlled setting.
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